Results 61 to 70 of about 3,351 (178)

Covalent inhibitors:A rational approach to drug discovery [PDF]

, 2020
Covalent inhibitors are recognized as an important component in drug discovery and therapeutics. Since the first appearance of covalent inhibitors in the late 18th century, the field has advanced significantly and currently about 30% of the marketed ...
Domling, Alexander, Konstantinidou, Markella, Sutanto, Fandi   +2 more
core   +1 more source

Quantitative Evaluation of Model‐Informed Drug Development Implementation in China's Approved Innovative Drugs: From Policy to Practice (2018–2024)

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Model‐informed drug development (MIDD) has emerged as a cornerstone paradigm in global pharmaceutical innovation. Historically underutilized in China, MIDD methodologies gained momentum following the National Medical Products Administration's (NMPA) 2020 release of the Model‐Informed Drug Development Technical Guideline, which was subsequently
Jian Li, Zhenlei Wang, Chunmin Wei, Ruirui He, Qingyu Yao   +4 more
wiley   +1 more source

Immune response to COVID‐19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy [PDF]

, 2023
Patients with Waldenström macroglobulinaemia (WM) are at increased risk of severe COVID-19 infection and have poor immune responses to COVID-19 vaccination. This study assessed whether a closely monitored pause in Bruton's Tyrosine Kinase inhibitor (BTKi)
Beaton, Brendan, Brilot, Fabienne, Hastak, Priyanka , Kelleher, Anthony D , Rankin, Katherine, Sasson, Sarah C , Trotman, Judith, Turville, Stuart , Warden, Andrew, Wong, Alexander, Yeola, Avani   +10 more
core   +2 more sources

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database

BMJ Open
Objective Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor that has been approved for the treatment of several B cell malignancies. The aim of this study was to evaluate adverse events (AEs) associated with zanubrutinib based on the
Ping Huang, Xiaochun Zheng, Miaomiao Zhang, Jiangfeng Wang, Jingyang Lin, Jinlong Huang, Xiuli Yang   +6 more
doaj   +1 more source

Multilevel network meta-regression for time-to-event outcomes in educational symposium. Indirect treatment comparison methodology matters:unlocking the essentials for robust analysis [PDF]

Indirect treatment comparisons (ITCs) are frequently required in health technology assessments due to the lack of head-to-head trials for interventions of interest.
Phillippo, David M
core   +3 more sources

Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans

Blood Advances, 2019
: The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has proven to be efficacious in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and related diseases.
Gasim Dobie, Fahd A. Kuriri, Musab M.A. Omar, Fehaid Alanazi, Ali M. Gazwani, Chloe P.S. Tang, Daniel Man-yuen Sze, Sasanka M. Handunnetti, Constantine Tam, Denise E. Jackson   +9 more
doaj   +1 more source

Updated Safety And Efficacy Data In The Phase 1 Trial Of Patients With Mantle Cell Lymphoma (Mcl) Treated With Bruton Tyrosine Kinase (Btk) Inhibitor Zanubrutinib (Bgb‐3111) [PDF]

, 2019
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149513/1/hon55_2630 ...
Atwal, S., Cull, G., Elstrom, R., Huang, J., Kim, W., Munoz, J., Opat, S., Phillips, T.J., Simpson, D., Tam, C.S., Trotman, J., Wang, M., Wei, R.   +12 more
core   +1 more source

Targeting the tumor microenvironment in chronic lymphocytic leukemia [PDF]

, 2021
he tumor microenvironment (TME) plays an essential role in the development, growth, and survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL).
Janum, Sine, Niemann, Carsten U, Patten, Piers E M, Ramsay, Alan G, Svanberg, Rebecka   +4 more
core   +2 more sources

Evolution of BTK inhibitors [PDF]

The purpose of this clinical review evaluates the evolution of bruton’s tyrosine kinase (BTK) inhibitors in becoming the standard of care in treating chronic lymphocytic leukemia (CLL).
Mathew, Dena
core   +2 more sources